The potential role of tomudex in the treatment of advanced colorectal cancer

Research output: Contribution to journalArticle

Abstract

Aims and Background: The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods: The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results: Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions: Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.

Original languageEnglish
Pages (from-to)576-580
Number of pages5
JournalTumori
Volume83
Issue number2
Publication statusPublished - Mar 1997

Fingerprint

Colorectal Neoplasms
Drug Administration Schedule
Drug Administration Routes
Quinazolines
Thymidylate Synthase
Therapeutics
Folic Acid
Quality of Life
Guidelines
raltitrexed
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Colorectal cancer
  • Tomudex

ASJC Scopus subject areas

  • Cancer Research

Cite this

The potential role of tomudex in the treatment of advanced colorectal cancer. / Sobrero, Alberto F.

In: Tumori, Vol. 83, No. 2, 03.1997, p. 576-580.

Research output: Contribution to journalArticle

@article{aceceb59846d4acba4408362d18fb544,
title = "The potential role of tomudex in the treatment of advanced colorectal cancer",
abstract = "Aims and Background: The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods: The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results: Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions: Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.",
keywords = "Colorectal cancer, Tomudex",
author = "Sobrero, {Alberto F.}",
year = "1997",
month = "3",
language = "English",
volume = "83",
pages = "576--580",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - The potential role of tomudex in the treatment of advanced colorectal cancer

AU - Sobrero, Alberto F.

PY - 1997/3

Y1 - 1997/3

N2 - Aims and Background: The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods: The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results: Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions: Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.

AB - Aims and Background: The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods: The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results: Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions: Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.

KW - Colorectal cancer

KW - Tomudex

UR - http://www.scopus.com/inward/record.url?scp=0030787765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030787765&partnerID=8YFLogxK

M3 - Article

C2 - 9226024

AN - SCOPUS:0030787765

VL - 83

SP - 576

EP - 580

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -